Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
David Steinberg
AddedMar 31, 2024
UpdatedMay 31, 2026
David Steinberg

David Steinberg

Board Member, Rectify Pharmaceuticals

CrunchbaseLinkedIn

David Steinberg's Career

Rectify Pharmaceuticals
Rectify Pharmaceuticals

Cambridge, MA, US

Board Member· Board
Photys Therapeutics
Photys Therapeutics
Board Member· Board
Be Biopharma
Be Biopharma

Cambridge, MA, US

Co-Founder & CEO· C-Suite · Management
Vedanta Biosciences
Vedanta Biosciences

Cambridge, MA, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

David Steinberg's Career

Rectify Pharmaceuticals
Rectify Pharmaceuticals

Cambridge, MA, US

Board Member· Board
Photys Therapeutics
Photys Therapeutics
Series A$75M382021
Board Member· Board

Leadership at Photys Therapeutics

Lizzie NgoLizzie NgoBoard Member

Similar to Photys Therapeutics

BlueLight TherapeuticsBlueLight TherapeuticsBurlingame, CA, USSmall Moleculesest. 2000BlueLight TherapeuticsBurlingame, CA, US · est. 2000

BlueLight Therapeutics develops novel therapeutic molecules for challenging drug targets using a proprietary platform.

Series C · $46.6M30
Initial TherapeuticsInitial TherapeuticsNew York City, NY, USMedicinesest. 2020Initial TherapeuticsNew York City, NY, US · est. 2020

Initial Therapeutics: An ATP company developing small-molecule medicines to prevent pathogenic protein synthesis.

Series A · $78.8M11
Be Biopharma
Be Biopharma
Series B$182M1192020Cambridge, MA, US
Co-Founder & CEO· C-Suite · Management

Leadership at Be Biopharma

Rich JamesRich JamesCo-Founder
David RawlingsDavid RawlingsCo-Founder
Lea HachigianLea HachigianCo-Founder
Aleks Radovic-MorenoAleks Radovic-MorenoCo-Founder

Similar to Be Biopharma

Bespoke BiotherapeuticsBespoke BiotherapeuticsSan Mateo, CA, USB-Cell Therapeuticsest. 2021Bespoke BiotherapeuticsSan Mateo, CA, US · est. 2021

Bespoke Biotherapeutics: Innovating custom B-cell therapies for enhanced cancer immunotherapy.

Angel · $256k2
HebeCellHebeCellNatick, MA, USCell Therapiesest. 2016HebeCellNatick, MA, US · est. 2016

MA-based HebeCell pioneers in immuno-oncology and regenerative medicine through cell-based therapeutics.

Series A · $63M24
SpheringenicsSpheringenicsAtlanta, GA, USCell Therapiesest. 2007SpheringenicsAtlanta, GA, US · est. 2007

SpherIngenics: Leading biotech firm specializing in innovative cell-based medicinal therapies.

Pre-Seed · $730k4
Beilai BioBeilai BioIrvine, CA, USStem Cell Therapiesest. 2015Beilai BioIrvine, CA, US · est. 2015

Beilai Bio, a California-based biopharmaceutical firm, develops stem cell therapies for high-need diseases.

Series B · $300M30
Vedanta Biosciences
Vedanta Biosciences

Cambridge, MA, US

Co-Founder

David Steinberg's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to David Steinberg

Juan EnriquezJuan EnriquezFounder & CEO · BiotechonomyVenkat KrishnanVenkat KrishnanCEO · BionpharmaDon DavidsonDon DavidsonCo-Founder · Creative BioTherapeuticsRob RichardsRob RichardsFounder · Biophyx